Pruckner, Philip
Mitsch, Christoph
Macher, Stefan
Krajnc, Nik
Marik, Wolfgang
Novak, Klaus
Wöber, Christian
Pemp, Berthold
Bsteh, Gabriel http://orcid.org/0000-0002-0825-0851
Funding for this research was provided by:
Medical University of Vienna
Article History
Received: 24 April 2023
Accepted: 15 July 2023
First Online: 31 August 2023
Conflict of interest
: P. Pruckner, C. Mitsch, S. Macher, W. Marik, K. Novak and B. Pemp declare that they have no competing interests. N. Krajnc: has participated in meetings sponsored by and received speaker honoraria or travel funding from Merck, Novartis and Roche, and held a grant for a Multiple Sclerosis Clinical Training Fellowship Programme from the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). C. Wöber: has received honoraria consultancy/speaking from Apomedica, Curelator, Eli Lilly, Grünenthal, Hermes, Novartis, Pfizer, and Ratiopharm/Teva. G. Bsteh: has participated in meetings sponsored by and received speaker honoraria or travel funding from Biogen, Celgene/BMS, Lilly, Merck, Novartis, Roche, Sanofi-Genzyme and Teva, and received honoraria for consulting from Biogen, Celgene/BMS, Novartis, Roche, Sanofi-Genzyme and Teva. He has received unrestricted research grants from Celgene/BMS and Novartis.